InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,469.30
(
0.39%
)
US TECH 100
19,199.20
(
0.13%
)
Dow Jones
39,112.16
(
0.00%
)
Brent Oil
84.71
(
0.62%
)
Bitcoin
61,330.25
(
-0.78%
)
Post# of 21475
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

chesster2010

Send PM Follow Ignore
Followers 0
Posts 77
Boards Moderated 0
Alias Born 06/11/2006

chesster2010

Re: None

Sunday, 04/09/2017 6:22:33 PM

Sunday, April 09, 2017 6:22:33 PM

Post# of 21475
TRPX new synthetic cannabinoid IPO. Only $25 mil market cap with phase IIa for Tourette's Syndrome. Raphael Mechoulam is on the Advisory board.

Great article below.

New IPO Stock Therapix BioSciences (NASDAQ:TRPX) Is Undervalued Compared To Peers – But Not For Long

Here's a look at how fresh IPO cannabis stock Therapix BioSciences (NASDAQ:TRPX) is taking advantage of synthetic cannabis to bring drugs to market quicker than its peers.

https://goo.gl/hHdGqC
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up